Highland Capital Management (Texas)’s Nektar Therapeutics NKTR Stock Holding History

Highland Capital Management (Texas)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-140	Closed	-$223K	–	361
2018 Q1	$223K	Sell	140 -150	-52%	-$193K	0.01%	310
2017 Q4	$260K	Sell	290 -477	-62%	-$282K	0.01%	276
2017 Q3	$276K	Sell	767 -900	-54%	-$282K	0.01%	266
2017 Q2	$489K	Hold	1,667	–	–	0.02%	212
2017 Q1	$587K	Sell	1,667 -5,000	-75%	-$1.12M	0.03%	221
2016 Q4	$1.23M	Buy	+6,667	New	+$1.36M	0.06%	159

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highland Capital Management (Texas)'s NKTR Position: Q2 2018 in Review

Highland Capital Management (Texas) sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 140 shares — an estimated $223K sold.

Highland Capital Management (Texas) first reported a position in NKTR in Q4 2016 and held it in 6 quarters. The position peaked at $1.23M in Q4 2016. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

Highland Capital Management (Texas) reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
Highland Capital Management (Texas) sold 140 Nektar Therapeutics shares in Q2 2018, an estimated $223K.
Highland Capital Management (Texas) first reported a position in Nektar Therapeutics in Q4 2016 and held it in 6 quarters.
Highland Capital Management (Texas)'s Nektar Therapeutics position peaked at $1.23M in Q4 2016.
379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2018, filed 14 Aug 2018.